Bronchiolitis Obliterans Syndrome Market is segmented By Therapy (Budesonide/Formoterol, Montelukast....
Market Size in USD Mn
CAGR4.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 4.1% |
Market Concentration | Medium |
Major Players | Zambon Pharma, Incyte Corporation, Genentech, GlaxoSmithKline, Altavant Sciences and Among Others |
The bronchiolitis obliterans syndrome market is estimated to be valued at USD 60.37 Mn in 2024 and is expected to reach USD 79.93 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031. The prevalence of bronchiolitis obliterans syndrome (BOS) is increasing which is driving the demand for effective therapeutics. With no approved drug therapy currently available for BOS, the pipeline drugs in late-stage clinical trials holds significant potential to capture market share if approved.